Details of the Drug Combinations

General Information of This Drug (ID: DMGVH6N)

• Drug Name: Axitinib (DMGVH6N)
• Synonyms: AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)

Indication

Renal cell carcinoma; ICD 11: 2C90; Status: Approved [1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Axitinib + Afatinib	DC0JU33	Afatinib	Endometriosis	[2]
Axitinib + Bosutinib	DC0NN1T	Bosutinib	Accelerated Phase Chronic Myelogenous Leukemia (CML)	[3]
Axitinib + Aflibercept	DCNGTTW	Aflibercept	Neovascular Age-related Macular Degeneration	[4]
Crizotinib + Axitinib	DC4BKE1	Crizotinib	Solid Tumors	[5]
Crizotinib + Axitinib	DCOWVBN	Crizotinib	Advanced Solid Tumors	[6]
Docetaxel + Axitinib	DCTHBM7	Docetaxel	Breast Neoplasms	[7]
Erlotinib + Axitinib	DC7G46O	Erlotinib	Neoplasms	[8]
Gemcitabine + Axitinib	DCGCBSA	Gemcitabine	Pancreatic Neoplasms	[9]
Lenvatinib + Axitinib	DC4BPE4	Lenvatinib	Advanced Renal Cell Carcinoma	[10]
Sunitinib + Axitinib	DC73CTF	Sunitinib	Kidney Neoplasms	[11]
Sunitinib + Axitinib	DCATK01	Sunitinib	Carcinoma	[12]
Talazoparib + Axitinib	DCGWDP7	Talazoparib	Kidney Cancer	[13]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5659).
• [2] ClinicalTrials.gov (NCT03481842) Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
• [3] ClinicalTrials.gov (NCT02782403) Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
• [4] ClinicalTrials.gov (NCT04626128) Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
• [5] ClinicalTrials.gov (NCT00828919) Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
• [6] ClinicalTrials.gov (NCT01999972) A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
• [7] ClinicalTrials.gov (NCT00076024) AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
• [8] ClinicalTrials.gov (NCT06161558) Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
• [9] ClinicalTrials.gov (NCT00219557) AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
• [10] ClinicalTrials.gov (NCT04522323) A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
• [11] ClinicalTrials.gov (NCT04669366) Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
• [12] ClinicalTrials.gov (NCT04033991) Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
• [13] ClinicalTrials.gov (NCT04337970) Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer